LYMPHOPENIA IS AN INDEPENDENT RISK-FACTOR IN PATIENTS WITH LOW-RISK MDS ACCORDING TO THE IPSS-R

被引：0
|
作者：
Silzle, T. [1 ]
Schuler, E. [2 ]
Hildebrandt, B. [3 ]
Blum, S. [4 ]
Haas, R. [2 ]
Germing, U. [2 ]
机构：
[1] Cantonal Hosp St Gallen, Oncol Haematol, St Gallen, Switzerland
[2] Univ Hosp Dusseldorf, Dept Haematol Oncol & Clin Immunol, Dusseldorf, Germany
[3] Univ Hosp Dusseldorf, Inst Human Genet, Dusseldorf, Germany
[4] CHU Vaudois, Dept Oncol, Lausanne, Switzerland
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P664
引用
收藏
页码：263 / 263
页数：1
相关论文
共 50 条
  • [41] WT1 mRNA Expression in the Peripheral Blood of Patients with MDS Yields Additional Prognostic Information within the IPSS-R Risk Categories "Very Low", "Low" and "Intermediate"
    Rautenberg, Christina
    Pechtel, Sabrina
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    Kobbe, Guido
    Schroeder, Thomas Michael
    BLOOD, 2018, 132
  • [42] Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories
    Pfeilstocker, Michael
    Tuechler, Heinz
    Ades, Lionel
    Cermak, Jaroslav
    Chermat, Fatiha
    Della Porta, Matteo G.
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Germing, Ulrich
    Haase, Detlef
    Kuendgen, Andrea
    Luebbert, Michael
    Magalhaes, Silvia Maria Meira
    Malcovati, Luca
    Miyazaki, Yasushi
    Sanz, Guillermo
    Santini, Valeria
    Sekeres, Mikkael A.
    Walter, Matthew J.
    Valent, Peter
    Greenberg, Peter L.
    BLOOD, 2022, 140 : 6976 - 6978
  • [43] Diagnosis of immune pathophysiology in patients with low-risk MDS
    Nakao, S.
    LEUKEMIA RESEARCH, 2009, 33 : S1 - S1
  • [44] TRANSFUSION BURDEN AMONG LOW-RISK MDS PATIENTS
    Dubow, J.
    Guerci, A.
    Gyan, E.
    Dupuis-Sireva, A.
    LEUKEMIA RESEARCH, 2021, 108 : S27 - S27
  • [45] AN IPSS-R CUTOFF POINT OF 3 STRATIFIED MYELODYSPLASTIC SYNDROMES PATIENTS INTO TWO RISK GROUPS
    Montoro Gomez, J.
    Pomares, H.
    Merchan, B.
    Molero, A.
    Alonso, E.
    Fernandez, M.
    Gallur, L.
    Grau, J.
    Salamero, O.
    Tazon-Vega, B.
    Blanco, A.
    Ortega, M.
    Sureda, A.
    Arnan, M.
    Valacarcel, D.
    LEUKEMIA RESEARCH, 2017, 55 : S145 - S146
  • [46] THE IPSS-R HAS PROGNOSTIC IMPACT IN UNTREATED PATIENTS WITH MDS DEL(5Q)
    Schemenau, J.
    Lauseker, M.
    Hildebrandt, B.
    Fenaux, P.
    Pfeilstoecker, M.
    Valent, P.
    Platzbecker, U.
    Kuendgen, A.
    Bug, G.
    Haas, R.
    Germing, U.
    LEUKEMIA RESEARCH, 2015, 39 : S157 - S157
  • [47] Stratification with monosomal karyotype improves prognostic value of IPSS-R in MDS patients treated with AZA
    Cluzeau, T.
    Mounier, N.
    Karsenti, J. M.
    Gastaud, L.
    Garnier, G.
    Re, D.
    Gutnecht, J.
    Montagne, N.
    Raynaud, S.
    Cassuto, J. P.
    LEUKEMIA RESEARCH, 2013, 37 : S80 - S80
  • [48] The IPSS-R has prognostic impact in untreated patients with MDS del(5q)
    Kaivers, J.
    Lauseker, M.
    Hildebrandt, B.
    Fenaux, P.
    Pfeilstoecker, M.
    Valent, P.
    Platzbecker, U.
    Latagliata, R.
    Oliva, E. N.
    Xicoy, B.
    Goetze, K.
    Ganster, C.
    Haase, D.
    Bug, G.
    Kuendgen, A.
    Gattermann, N.
    Haas, R.
    Germing, U.
    LEUKEMIA RESEARCH, 2018, 72 : 27 - 33
  • [49] NOVEL APPROACHES IN LOW-RISK MDS
    Platzbecker, Uwe
    LEUKEMIA RESEARCH, 2021, 108 : S59 - S59
  • [50] Refined cytogenetic IPSS-R evaluation by the use of SNP array in a cohort of 290 MDS patients
    Scarpelli, Ilaria
    Stalder, Valerie Beyer
    Tsilimidos, Gerasimos
    Rapakko, Katrin
    Costanza, Mariangela
    Blum, Sabine
    Schoumans, Jacqueline
    GENES CHROMOSOMES & CANCER, 2023, 62 (12): : 721 - 731
12345